The UNAIDS 10-point plan for making progress on prevention omits elements of the “research-to-rollout” continuum, and leaves the definition of prevention out—focusing on the “how” rather than the “what”. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
The UNAIDS 10-Point Plan for Making Progress on Prevention
US Public Sector Investment in HIV Prevention R&D, Compared to All Other Funding, 2012–2016
This graphic tracks US public sector investment in HIV prevention research & development vs all other funding sources over the four year period of 2012-2016. For much more on HIV prevention research & development funding, visit www.hivresourcetracking.org.
Driving Product Introduction and Access
AVAC has always advocated for closing critical prevention gaps. Now we’re taking our mission further. With African and global partners, we’re stepping beyond advocacy to generate the knowledge and tools that countries need to more quickly deliver new advances.
We’re engaging directly with national decision-makers to identify and overcome delivery hurdles for PrEP. We’re examining the preferences and experiences of people at high risk for HIV, so that future tools—long-acting injectables, vaginal rings and others—can be optimized to meet their needs.
Investment in HIV Prevention Research & Development
Because money matters as much as messages, this Px Wire centerspread summarizes current investments, and trends over time, in HIV-prevention research and development. This full-color feature is excerpted from the recently-released report on HIV prevention research and development investment produced by AVAC and partners in the field.
South African HIV Prevention Research and Demonstration Sites
South Africa’s Trial Sites: An overview of HIV prevention research and demonstration sites in 2017, by location and intervention.
Evolving Context for HIV Prevention Research (Map)
A global map showing selected HIV prevention research and oral PrEP status.
Global HIV Prevention R&D Investment by Technology Category, 2000-2016
In 2016, funding for HIV prevention R&D decreased by 3 percent (US$35 million) from the previous year, falling to US$1.17 billion. Funding in 2016 signals the lowest annual investment in HIV prevention R&D in more than a decade.
Composition of the Global HIV Prevention R&D Investment Base, 2015-2016
The call for a more diverse base of funders in the prevention R&D landscape is not a new one, but recent trends display greater polarization and a more extreme funding imbalance. In 2016, 75 percent of the overall funding came from the US public sector. Together, the US public sector and the BMGF represented 88 percent of the total global investment in 2016, compared to 81 percent in 2015.
Excerpted from our HIV prevention research tracking report, visit here for all graphics from the report.
HIV Prevention R&D Trial Participants by Region, 2016
HIV prevention research cannot be conducted without those who volunteer to participate in clinical trials or without the engagement of communities in which those trials take place. In 2016, there were almost 700,000 participants in HIV prevention research trials, primarily based in sites with high HIV/AIDS burdens in Africa, Asia, Latin America and the US.
Excerpted from our HIV prevention research tracking report, visit here for all graphics from the report.
From Proof-of-Concept to Prevention Phenomenon in Five Years
This timeline, first appearing in AVAC Report 2014/15: HIV Prevention on the Line, shows PrEP going from proof-of-concept to prevention phenomenon in five years and can be used to anticipate and speed action on the next generation of ARV-based prevention options.